---
figid: PMC4382495__12105_2015_619_Fig2_HTML
figtitle: Signaling pathways involved in thyroid carcinogenesis and tumor progression
organisms:
- NA
pmcid: PMC4382495
filename: 12105_2015_619_Fig2_HTML.jpg
figlink: /pmc/articles/PMC4382495/figure/Fig2/
number: F2
caption: 'Signaling pathways involved in thyroid carcinogenesis and tumor progression.
  Growth factors induce receptor tyrosine kinase dimerization, resulting in tyrosine
  phosphorylation within the cytoplasmic tail, leading to RAS activation. Through
  the subsequent activation of BRAF and MEK, ERK is activated and translocates to
  the nucleus, where it activates various transcription factors. Similarly, the mTOR
  pathway is activated. In aggressive thyroid carcinomas, E-cadherin is down-regulated
  and β-catenin is stabilized and translocates to the nucleus; this and other epigenetic
  alterations can upregulate cyclin D1. Adhesion can be altered by multiple mechanisms,
  including adhesion molecules and growth factors, to impact tumor-stromal interactions.
  BRAF-like tumors show robust activation of MAPK signaling pathway, while RAS-like
  tumors activate both MAPK (to a lesser extent than BRAF-like tumors) and Akt-mTOR
  pathway, using p90RSK as a crucial cross-link to bcl-2 signaling []. Abbreviations:
  Akt protein kinase B, BAD bcl-2 associated death promoter, bcl-2 B cell lymphoma
  2, ERK extracellular-signal-related kinase, FGF fibroblast growth factor, FGFR FGF
  receptor, MEK mitogen activated protein kinase kinase, mTOR mechanistic target of
  rapamycin, RTK receptor tyrosine kinase, VEGF vascular endothelial growth factor,
  VEGFR VEGF receptor'
papertitle: 'When Thyroid Carcinoma Goes Bad: A Morphological and Molecular Analysis.'
reftext: Sylvia Papp, et al. Head Neck Pathol. 2015 Mar;9(1):16-23.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9262468
figid_alias: PMC4382495__F2
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC4382495__F2
ndex: 0deaa237-df06-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4382495__12105_2015_619_Fig2_HTML.html
  '@type': Dataset
  description: 'Signaling pathways involved in thyroid carcinogenesis and tumor progression.
    Growth factors induce receptor tyrosine kinase dimerization, resulting in tyrosine
    phosphorylation within the cytoplasmic tail, leading to RAS activation. Through
    the subsequent activation of BRAF and MEK, ERK is activated and translocates to
    the nucleus, where it activates various transcription factors. Similarly, the
    mTOR pathway is activated. In aggressive thyroid carcinomas, E-cadherin is down-regulated
    and β-catenin is stabilized and translocates to the nucleus; this and other epigenetic
    alterations can upregulate cyclin D1. Adhesion can be altered by multiple mechanisms,
    including adhesion molecules and growth factors, to impact tumor-stromal interactions.
    BRAF-like tumors show robust activation of MAPK signaling pathway, while RAS-like
    tumors activate both MAPK (to a lesser extent than BRAF-like tumors) and Akt-mTOR
    pathway, using p90RSK as a crucial cross-link to bcl-2 signaling []. Abbreviations:
    Akt protein kinase B, BAD bcl-2 associated death promoter, bcl-2 B cell lymphoma
    2, ERK extracellular-signal-related kinase, FGF fibroblast growth factor, FGFR
    FGF receptor, MEK mitogen activated protein kinase kinase, mTOR mechanistic target
    of rapamycin, RTK receptor tyrosine kinase, VEGF vascular endothelial growth factor,
    VEGFR VEGF receptor'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Tie
  - Ras85D
  - InR
  - ras
  - Ras64B
  - l(1)G0020
  - Taf4
  - Pi3K92E
  - Rpn2
  - Sap-r
  - Myb
  - Pi3K21B
  - Taf5
  - pk
  - Akt
  - cass
  - shg
  - Debcl
  - arm
  - Erk7
  - rl
  - Dsor1
  - Mtk
  - Mtor
  - Tor
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Pvf1
  - Pvf2
  - Pvf3
  - Pvr
  - CycE
  - cyc
  - bnl
  - as
  - Is
  - btl
  - htl
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - KRAS
  - HRAS
  - NRAS
  - CUX1
  - SART3
  - PIK3R1
  - PIK3R2
  - ARHGEF7
  - CBFA2T2
  - PPP1R13B
  - PPP1R12C
  - AKT1
  - AKT2
  - AKT3
  - BAD
  - BRAF
  - CDH1
  - FZR1
  - BCL2
  - CTNNB1
  - EPHB2
  - MAPK1
  - MAPK3
  - RPS6KA1
  - RPS6KA2
  - RPS6KA3
  - RPS6KA4
  - RPS6KA5
  - RPS6KA6
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MTOR
  - CCND1
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - KDR
  - FLT1
  - FLT4
  - Cancer
---
